Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al

Eur J Cancer. 2018 Mar:92:121-122. doi: 10.1016/j.ejca.2018.01.070. Epub 2018 Feb 9.

Authors

Takayuki Yoshino¹, Yanzhi Hsu², Federico Nasroulah³

Affiliations

¹ National Cancer Center Hospital East, Chiba, Japan. Electronic address: tyoshino@east.ncc.go.jp.
² Eli Lilly and Company, Bridgewater, NJ, USA.
³ Eli Lilly and Company, Buenos Aires, Argentina.

PMID: 29433790
DOI: 10.1016/j.ejca.2018.01.070

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Carcinoembryonic Antigen*
Colonic Neoplasms
Colorectal Neoplasms
Humans
Ramucirumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Carcinoembryonic Antigen